How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Now that Pres­i­dent-elect Don­ald Trump has made his choice for FDA com­mis­sion­er, re­ac­tions and analy­sis are pour­ing in from bio­phar­ma ex­ec­u­tives and for­mer staffers who …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.